Pacific Biosciences (PACB) Proxy filing summary

Executive summary

• Focus on enabling genomics to improve human health through highly accurate HiFi long-read sequencing technology.

• Launched two sequencers, Vega and Revio, to address both high and low throughput needs, with significant market adoption and consumables growth.

• Forward-looking statements highlight anticipated market opportunities, product expansion, and ongoing innovation in sequencing technology.

Voting matters and shareholder proposals

• Proposals include electing six directors for one-year terms, ratifying Ernst & Young LLP as auditor for FY 2026, a non-binding advisory vote on executive compensation, and amending the 2020 Equity Incentive Plan to add 16 million shares.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Director nominees bring expertise in healthcare, genomics, finance, and executive leadership, with backgrounds in major institutions and companies.

• Moving toward annual election of all directors to enhance accountability.